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Abstract
Background: Population studies have shown an inverse association between high-density lipoprotein (HDL)
cholesterol levels and risk of coronary heart disease (CHD). HDL has different functions, including the ability to
protect biological molecules from oxidation. Our aim was to evaluate the performance of two fluorescence-based
assays in assessing the antioxidative capacity of HDL.
Methods: We compared the antioxidative capacity of HDL with the phospholipid 2’,7’-dichlorodihydrofluorescein
(DCF) assay and the dihydrorhodamine 123 (DHR) assay in controls and in subjects at increased risk of CHD, including
subjects with established CHD, and subjects with elevated plasma triglycerides (TG), serum amyloid A (SAA), or
myeloperoxidase (MPO) levels.
Results: The antioxidative capacity of HDL, as measured by the DCF assay, was significantly lower in both CHD and
high-TG patients than in controls (p < 0.001 and p = 0.004, respectively). Interestingly, the mean antioxidative capacity
of HDL in high-SAA subjects was significantly higher (p < 0.03), while in high-MPO subjects was similar to controls.
When the DHR assay was used we did not find differences in HDL’s antioxidative capacity between CHD patients and
controls but we found higher antioxidative capacity in high-SAA subjects compared to controls.
Conclusions: Only the DCF assay could detect significant differences in the antioxidative capacity of HDL between
controls and CHD subjects. Practical use of both assays for the assessment of antioxidative capacity of HDL is limited by
the large overlap in values among groups. The antioxidative activity of HDL in patients who have elevated SAA levels
needs to be reassessed.
Keywords: High density lipoprotein, Oxidation, Coronary heart disease, Fluorescence assay
Background
The epidemiological evidence of an inverse association
between plasma high-density lipoprotein cholesterol
(HDL-C) levels and risk of cardiovascular disease is well
established [1, 2]. HDL can protect against the develop-
ment and progression of atherosclerosis by promoting re-
verse cholesterol transport (RCT), maintaining endothelial
function, and reducing inflammation and oxidation [3]. In
subjects who had undergone assessment of cardiovascular
disease by coronary angiography or carotid intima-media
thickness, the cholesterol efflux capacity of HDL was
shown to be inversely associated with the extent of cardio-
vascular disease, independent of plasma HDL-C and apoli-
poprotein A-I (apoA-I) levels [4]. However, it has also
been shown that inflammatory conditions or oxidative
stress may impair the protective functions of HDL [5, 6].
In subjects receiving a low-dose endotoxin injection, a
reduction in the functional capacities of HDL that was not
consistent with the changes in HDL-C or apoA-I levels
has been observed [7]. Therefore, it is now suggested that
measurement of HDL functional capacity may be a better
predictor of cardiovascular disease risk than HDL-C levels.
Navab et al. [8] and Kelesidis et al. [9] have developed
cell-free assays to measure the antioxidative activity of
HDL, one of the functional capacities of HDL, using fluor-
escence probes. A number of studies using these assays
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have shown an impaired antioxidative activity of HDL in
patients with both acute and chronic inflammatory disor-
ders such as acute coronary syndrome (ACS), systemic
lupus erythematosus, and diabetes [5, 6, 10]. In these stud-
ies, although the assays could detect differences between
control subjects and patients, there was considerable over-
lap between the groups and large standard deviation of the
mean values.
To validate the performance of the fluorescence probe-
based antioxidative assays, we sought to determine whether
these assays could detect differences between apparently
healthy subjects and patients whose conditions are thought
to impair the antioxidative activity of HDL.
Methods
Subjects and samples
Venous blood samples were collected from 160 apparently
healthy subjects (controls), 98 patients with cardiovascular
disease, 37 subjects with elevated triglyceride (TG) levels
(>250 mg/dL), 40 subjects with elevated serum amyloid A
(SAA) levels (>300 mg/L), and 30 subjects with elevated
serum myeloperoxidase (MPO) levels (>500 pmol/L).
Mean age of control and CHD subjects was 58 ± 16 and
61 ± 7 years, respectively. Control subjects had normal
plasma total cholesterol (TC), TG and low-density lipo-
protein cholesterol (LDL-C) levels (less than 200, 150, and
160 mg/dL, respectively). Subjects with cardiovascular
disease had established coronary heart disease (CHD),
defined as history of previous MI, stable angina, a
catheterization report of ≥50 % stenosis of at least one
coronary artery, abnormal exercise tolerance test or
nuclear imaging procedure, or angioplasty. Hypertension
was present in 4.5 % of controls and in 48 % of CHD sub-
jects and type 2 diabetes in 3.4 % of controls and 19 % of
CHD subjects. Also, hypertension was present in 13 % of
high TG, 10 % of high SAA and 11 % of high MPO sub-
jects, while diabetes was present in 9 % of high TG, 10 %
of high SAA and 6 % of high MPO subjects.
Plasma and serum samples were obtained by centrifuga-
tion and immediately stored at −80 °C until measurement.
Only plasma or serum were available in some study
subjects, therefore, appropriate plasma and serum controls
were used. The HDL antioxidative activity was measured in
different biological samples: HDL fractions obtained by
ultracentrifugation (UCHDL), apoB-depleted (apoBd)
plasma, or apoBd serum. ApoBd plasma (or serum) sam-
ples were obtained by adding 0.4 parts of a polyethylene
glycol (PEG) 6000 solution (Qiagen, Valencia, CA) (20 %
PEG in 200 mM glycine buffer, pH 7.4) to 1 part plasma
(or serum) followed by centrifugation at 10,000 g for
30 min at 4 °C. ApoBd samples were assayed within one
hour. UCHDL samples were separated by density-gradient
ultracentrifugation (density = 1.063–1.210 g/mL) followed
by dialysis at 4 °C. UCHDL samples were assayed within
three hours after dialysis.
Laboratory measurements
Total cholesterol, low-density lipoprotein cholesterol
(LDL-C), HDL-C, TG, and apoA-I levels were measured
using automated standardized assays from Roche (In-
dianapolis, IN). Small-dense LDL-C (sdLDL-C) levels
were measured using kits provided by Denka-Seiken
(Tokyo, Japan) [11]. SAA and MPO levels were mea-
sured using kits from Siemens on a Dimension and a
BNII clinical chemistry system, respectively. The apoA-
I-containing HDL subpopulation profile was determined
by non-denaturing two-dimensional gel electrophoresis
as previously described [12]. High sensitivity C reactive
protein (hs-CRP), glucose and insulin levels were mea-
sured in a central laboratory using established assays.
Measurement of the antioxidative activity of HDL
The antioxidative activity of HDL was measured by two
different fluorescence-based cell-free assays.
The antioxidant capacity of HDL was measured in 269
subjects by Vascular Strategies (Plymouth Meeting, PA)
using the organic phospholipid 2’,7’-dichlorodihydro-
fluorescein (DCF) diacetate probe, as previously de-
scribed by Navab et al. [8]. This assay is based on the
inhibition of oxidation of the fluorescence probe by
HDL. Briefly, apoBd plasma or serum samples were in-
cubated with oxidized LDL and DCF diacetate. In the
presence of oxidized LDL, DCF diacetate was converted
to DCF, its fluorescence form. The fluorescence excita-
tion/emission was measured at a 485/528 nm for one
hour. To calculate the antioxidant value of HDL of each
sample, the fluorescence intensity was divided by a refer-
ence value. This ratio is commonly referred to as the
HDL inflammatory index (HII) [8]. A value > 1.0 indi-
cates dysfunctional (pro-oxidant) HDL, while values <
1.0 indicate normal (antioxidant) HDL. The second assay
was used in our laboratory to determine the antioxida-
tive activity of HDL using the dihydrorhodamine 123
(DHR) as the fluorescence probe [9]. DHR (Life Tech-
nologies, Gaithersburg, MD) was dissolved in dimethyl
sulfoxide (DMSO) to a 50 mM DHR stock concentra-
tion. Iron-free buffered saline was prepared as follows:
60 nM of deferoxamine mesylate (Sigma-Aldrich, Saint
Louis, MO) was added to HBS buffer (HEPES 20 mM,
NaCl 150 mM, pH 7.4) followed by treatment with
1.0 g/dL of Chelex® 100 resin (Bio-Rad, Hercules, CA),
as previously described [13]. The concentrated DHR stock
reagent was diluted 1:1000 in the iron-free HBS buffer to
the 50 μM DHR working solution just before use. Five μg
of HDL-C of either UCHDL or apoBd samples was added
to each well in a 96-well flat bottom black plate (Fisher
Scientific, Waltham, MA). The volume of each well was
Tsunoda et al. Lipids in Health and Disease  (2016) 15:163 Page 2 of 8
adjusted to 150 μL using the iron-free HBS buffer.
Then, 25 μL of the 50 μM DHR solution was added to
reach a final DHR concentration of 7 μM and the plate
was immediately placed into an FLx800 Fluorescence
Reader ® (BioTek, Winooski, VT). Samples were run in
quadruplicate and a standard sample was added to each
assay plate. The fluorescence intensity of oxidized DHR
was assessed at five-minute intervals for one hour at
485/528 nm excitation/emission. The oxidative rate of
DHR (ORD) was calculated as the linear regression
slope of the fluorescence intensity between 10 and
60 min as calculated with Microsoft Excel software.
The ORD value of each sample was determined as the
mean of the quadruplicate slopes.
For both assays, the lower the number, the higher the
antioxidant capacity of HDL.
Statistical analysis
Statistical analyses were performed with the SPSS software
version 22 (IBM SPSS, IBM Corporation, Somers, NY).
Variables with normal distribution were expressed as
mean ± SD and those with non-normal distribution were
expressed as median and interquartile ranges. Differ-
ences between values among groups were tested by
Mann-Whitney U test. Spearman correlation coeffi-
cients describe the relationships between variables.
Statistical significance was accepted at p < 0.05.
Results
Antioxidant capacity of HDL as measured by the DCF assay
Analysis of antioxidative capacity of apoB-depeted (apoBd)
samples, as assessed with the DCF assay, in control subjects
revealed no significant differences between men and
women (Table 1). Therefore, in subsequent analyses, men
and women were combined in one group. However, serum
samples had significantly lower antioxidative capacity than
plasma samples (Table 1); therefore, in our analyses we
matched for sample type.
Characteristics of control subjects and patients whose
DCF values were measured in apoBd plasma or serum
are described in Table 2. All the lipid parameters in
CHD patients and high TG subjects were significantly
different from those in controls, except for apoA-I levels
which were similar in controls and CHD patients. The
CHD, high TG, and high SAA subjects had significantly
higher TG levels than controls, and this was associated
with lower HDL-C levels and altered distribution of
HDL particles. Median DCF values in both CHD
patients and high TG patients were significantly higher
(indicating reduced antioxidative activity of HDL) than
in controls (p < 0.001 and p = 0.004, respectively) (Fig. 1).
Although high SAA subjects had lower HDL-C and
higher TG levels than controls, their mean DCF value
was significantly lower (better antioxidative activity of
HDL) than that of controls (p = 0.03) (Fig. 1). In subjects
with high MPO, serum lipids were similar to those of
controls, with the exception of HDL-C (Table 2). The
antioxidative capacity of HDL as measured in apoBd
serum in high MPO subjects was similar to that of con-
trols (0.356 ± 0.035 and 0.378 ± 0.056, respectively).
Correlations between HDL subpopulations and HDL
antioxidative capacity
HDL’s antioxidative capacity was inversely associated with
the relative (%) concentrations of the small preβ-1 and α-3
HDL particles (r = −0.162, p = 0.030, and r = −0.155, p =
0.037, respectively), and was positively associated with
HDL-C concentrations and percent distribution of the




Men Women Men Women
N 30 29 32 25
Men/women 30/0 0/30 32/0 0/25
Age, y 59 ± 17 56 ± 16 56 ± 18 59 ± 14
TC, mg/dL 157 ± 28 175 ± 24 185 ± 39 189 ± 38
HDL-C, mg/dl 53 ± 11 67 ± 13* 53 ± 13 68 ± 15*
LDL-C, mg/dL 93 ± 21 95 ± 17 117 ± 36 103 ± 27
TG, mg/dL 87 ± 37 78 ± 23 102 ± 30 95 ± 39
sdLDL-C, mg/dL 17 ± 7 19 ± 8 27 ± 8 25 ± 12
Apo A-I, mg/dL 148 ± 19 170 ± 25 154 ± 28 182 ± 28
Antioxidative capacity of HDL (HII) 0.28 ± 0.04 0.30 ± 0.05 0.38 ± 0.06** 0.38 ± 0.05**
*p < 0.05, compared to men
**p < 0.05 compared to plasma
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Table 2 Plasma or serum lipid profiles in control subjects and patients whose HDL antioxidative activities were measured in apoBd
plasma or serum, respectively, with the DCF assay
Plasma Serum
Controls CHD High TG High SAA Controls High MPO
Number 59 58 37 28 57 30
M/F, n 30/29 54/4** 25/12 19/9 32/25 15/15
TC, mg/dL 165 ± 26 145 ± 29** 262 ± 178** 163 ± 44 188 ± 38 169 ± 46
HDL-C, mg/dL 59 ± 14 43 ± 13** 34 ± 15** 51 ± 17* 60 ± 15 49 ± 16*
LDL-C, mg/dL 94 ± 19 80 ± 23** 115 ± 68* 89 ± 6 112 ± 35 100 ± 41
TG, mg/dL 74 (63–99) 128 (88–170)** 324 (264–1080)** 115 (92–163)* 97 (70–123) 116 (93–146)
sd LDL-C, mg/dL 16 (14–19) 37 (27–44)** 41 (27–63)** 17 (12–27) 25 (18–32) 23 (19–30)
Apo A-I, mg/dL 158 ± 23 152 ± 34 129 ± 45** 148 ± 48 168 ± 29 149 ± 33
Glucose, mg/dL 110 ± 17 103 ± 31 164 ± 80 110 ± 21 92 ± 15 105 ± 23
Insulin μIU/mL 13.2 ± 13.1 15.1 ± 9.5 19.8 ± 12.1 14.1 ± 7.2 8.3 ± 5.1 22.0 ± 13.5
Hs-CRP, mg/L 1.7 ± 1.9 2.4 ± 4.9 7.9 ± 15.1 5.5 ± 4.4 1.3 ± 1.2 2.7 ± 11.6
HDL distribution
Preβ-1, % 8 (6–10) 12 (9–15)** 15 (10–19)** 8 (6–11) 5 (4–7) 5 (4–7)
α-1, % 23 (20–28) 15 (12–19)** 11 (7–17)** 17 (12–21)** 22 (19–25) 20 (16–22)
α-2, % 44 (42–47) 42 (39–45)* 41 (36–44)* 54 (49–61)** 41 (37–44) 40 (39–43)
α-3, % 15 (13–16) 18 (16–20)** 17 (13–23)** 11 (9–15)** 13 (12–15) 15 (13–17)
α-4, % 10 (8–11) 12 (10–14)** 13 (10–16)** 6 (5–9)** 11 (9–12) 12 (10–14)
Data are shown as mean ± SD or median (interquartile range). Differences in values between each group and Controls were tested by Pearson chi-squared test,
Student-t test or Mann-Whitney’s U test (*p < 0.05 and **p < 0.01, relative to Controls)
Fig. 1 Distribution and median values of the antioxidant capacity of HDL as assessed by the DCF assay in apoBd plasma samples of apparently
healthy subjects (Controls), patients with cardiovascular disease (CVD patients), patients with high triglyceride levels (High TG patients), and
patients with high serum amyloid A levels (High SAA patients). Differences between groups were tested by Mann-Whitney U test
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intermediate size α-2 HDL particles (r = 0.198 p = 0.008
and r = 0.246, p = 0.001, respectively) (Table 2).
Antioxidant capacity of HDL as measured by the DHR
assay
Plasma lipid profiles of the subjects whose oxidation rate
(ORD) were measured with the DHR assay are shown in
Table 3. HDL-C and apoA-I levels were lower in CHD pa-
tients than in controls. Plasma lipid profiles of high-SAA
subjects were not significantly different from controls.
ORD was measured using both UCHDL and apoBd
plasma in control and CHD subjects. The median level of
HDL antioxidative capacity was similar in controls and
CHD patients, whether measured using UCHDL or apoBd
plasma samples (Fig. 2). However, the antioxidant capacity
was significantly higher in UCHDL than in apoBd plasma
(both p < 0.001) (Fig. 2). High SAA subjects had signifi-
cantly lower median ORD value (better antioxidative
activity of HDL) compared to controls. Unexpectedly,
there was an inverse association between the ORD values
obtained from UCHDL and apoBd plasma (Spearman cor-
relation coefficient: −0.264, p = 0.024) (Fig. 3).
Discussion
It has been proposed that HDL can protect against ath-
erosclerosis by reducing LDL oxidation and protecting
cells from oxidative stress, important players in the de-
velopment and progression of atherosclerotic lesions
[14]. A number of studies using the DCF assay have
demonstrated that patients with chronic inflammatory
diseases have lower antioxidative capacity (higher DCF
values, expressed as HII) compared to healthy subjects
[15–17]. Recently, it has also been reported that higher
HII values are associated with increased mortality in
critically ill patients [18]. On the other hand, another
study has shown that, while acute coronary syndrome
patients had significantly higher than normal HII values,
no differences were observed between chronic CHD pa-
tients and healthy subjects [5]. These results suggest that
the DCF assay can detect alterations in the antioxidative
potential of HDL in some, but not all patient populations.
Similarly, in our study, we have shown that the antiox-
idative capacity of HDL assessed by the DCF assay is sig-
nificantly lower in CHD patients (higher HII) than in
healthy subjects. High TG levels were also associated
with decreased antioxidant capacity. However, it should
be noted that none of the CHD subjects in our study
had a DCF value, or HII index, above 1, a set limit of
pro-inflammatory HDL. Moreover, other conditions that
are believed to be associated with dysfunctional HDL,
such as elevated SAA or MPO levels were not associated
with impaired antioxidative capacity [19]. Actually, sub-
jects with elevated SAA levels showed a higher antioxi-
dant capacity than controls. Similarly to other studies,
our study documented a large overlap in the measures
of antioxidative activities of HDL among controls and
diseased subjects.
HDL particles are heterogeneous in size, composition
and function [12]. A number of studies have revealed
that various HDL subpopulations are differently associ-
ated with the antioxidative activity of HDL. Kontush et
al. [20, 21] demonstrated that in normolipidemic sub-
jects, the smaller HDL3 fraction had more favorable bio-
logical and functional properties than the larger HDL2
fraction and that the antioxidative activity of HDL was
predominantly associated with HDL3. Other researchers
have shown that, in diabetic patients, unfavorable
changes in the chemical composition and enzyme activ-
ities of HDL3 are associated with reduced antioxidative
activity of HDL [22, 23]. Our data indicating a significant
correlation between and HDL-C and HDL antioxidant
capacity is in line with others’ data [5]. When we mea-
sured HDL subpopulations, we observed an inverse cor-
relation between DCF and α-2 HDL particles. This HDL
subpopulation is found mostly in the HDL3 fraction
[23]. Therefore, our findings are in agreement with pre-
vious studies and support a specific involvement of the
normally most abundant HDL particle, α-2 in the anti-
oxidative capacity of HDL. Interestingly, LDL-C levels
also correlated inversely with DCF value: it is possible
that statin use in the CHD patients explains this unex-
pected result, since statin therapy has been previously
shown to improve DCF values [5]. In contrast to total
LDL-C, sdLDL-C, the most atherogenic fraction of LDL,
had a positive correlation with DCF values.
Our data also indicate that DCF values were higher in
serum than in plasma samples. This difference may be
explained, at least in part, by the antioxidant effects of
fibrinogen [24]. This raises the question whether we can
measure HDL’s antioxidative capacity in apoBd samples
Table 3 Plasma lipid profiles of control subjects and patients
whose HDL antioxidative capacity was measured in
ultracentrifuged HDL (UCHDL) and apoBd plasma samples using
the DHR assay
Controls CHD High SAA
Number 41 40 12
M/F, n 14/27 22/18 7/5
TC, mg/dL 174 ± 36 171 ± 41 193 ± 79
HDL-C, mg/dL 66 ± 18 53 ± 17** 72 ± 58
LDL-C, mg/dL 102 ± 27 99 ± 36 99 ± 44
TG, mg/dL 93 (68–122) 103 (77–153) 84 (62–133)
sd LDL-C, mg/dL 23 (17–29) 38 (23–45) 27 (17–32)
Apo A-I, mg/dL 172 ± 29 156 ± 33* 168 ± 78
Data shown as mean ± SD or median (interquartile range). P value of the male-
to-female ratio between the patients with cardiovascular disease and the con-
trol subjects is 0.059 analyzed by chi-squared test
*p < 0.05, **p < 0.01 compared to controls
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which contains a large number of other potentially redox
compounds. On the other hand, it is well documented
that HDL goes through significant alteration during ul-
tracentrifugal separation, which might alter its redox
capacity.
When the DHR assay was used to measure HDL anti-
oxidative capacity, we did not observe a significant dif-
ference between the median values in controls and CHD
patients. A previous study using the DHR assay has
shown that, although HDL from patients with psoriasis
Fig. 2 Distribution and median values of the oxidation rate of DHR (ORD) of ultracentrifuged HDL fractions (UCHDL) from apparently healthy
subjects (Controls) and patients with the cardiovascular disease (CVD patients), and of apoB-deleted (apoBd) plasma from Controls, CVD patients,
and patients with high serum amyloid A protein levels (High SAA patients). Differences between groups were tested by Mann-Whitney U test
Fig. 3 Correlation between the oxidation rate of DHR (ORD) of ultracentrifuged HDL fraction (UCHDL) and of apoB-depleted (apoBd) plasma in
apparently healthy subjects and patients with cardiovascular disease
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had lower cholesterol efflux capacity than control sub-
jects, there was no difference in the HDL antioxidant
capacity between the two groups [25]. Kelesidis et al.
[26], who had developed the DHR assay, have described
some of the limitations of the assay and reported that
the ORD value is susceptible to not only environmental
factors but also to factors associated with lipoproteins,
such as type and concentration of each lipoprotein par-
ticle, profile of apolipoproteins, and lipoprotein-isolation
methods. For example, the weight of added LDL, a pro-
inflammatory lipoprotein particle, correlated significantly
and inversely with the DHR value. Moreover, in our
study, the median ORD value from UCHDL samples
was significantly higher than that of apoBd samples: fur-
thermore, the ORD values of UCHDL samples corre-
lated negatively with those of apoBd samples. Similarly,
Kelesidis et al. have observed differences between
UCHDL and apoBd serum values, as indicated by
median ORD value in patients infected by HIV being
significantly higher than in healthy subjects when using
apoBd serum samples but lower when using UCHDL
samples [26]. Based on these data and the results of our
study, DHR should be considered an unsuitable fluores-
cent probe for the measurement of the antioxidative
activity of HDL.
SAA, an acute-phase protein primarily synthesized by he-
patocytes, replaces apoA-I in HDL and forms monodis-
perse (α-2) HDL particles. A number of experimental
studies have suggested that SAA can accelerate atheroscler-
osis possibly by impairing the antioxidative capacity of
HDL [27, 28]. In contrast, our study indicated that patients
with high SAA levels had significantly lower ORD or DCF
values (better antioxidative activity of HDL) than controls.
A limitation of our study was that we did not have
complete information on medical histories and medications
in all of our study subjects. Another potential limitation is
that the number of the subjects might be too small to yield
significant results about the DHR assay.
Conclusions
We are led to the following conclusions: 1) the anti-
oxidant capacity of HDL is affected by the medium:
apoB-depleted plasma and serum, and ultracentrifu-
gally isolated HDL exert different antioxidant capacity;
2) although the DCF assay could detect significant dif-
ferences in the antioxidative activity of HDL between
controls and patients, the practical use of this assay is
limited by the large overlap in values among groups;
3) the DHR assay failed to measure accurately the
antioxidative activity of HDL, possibly due to the sus-
ceptibility of the probe to various factors; and 4) the
antioxidative activity of HDL in patients who have ele-
vated SAA levels needs to be reassessed.
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